Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-resistant Ovarian Cancer (PROC)”

20 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 20 results

Not applicableEnrolling By InvitationNCT07035067
What this trial is testing

Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada

Who this might be right for
Ovarian CancerCaregiver BurdenPatient Burden
PeriPharm 150
Testing effectiveness (Phase 2)Study completedNCT03657043
What this trial is testing

Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Seagen Inc. 98
Testing effectiveness (Phase 2)Ended earlyNCT03311334
What this trial is testing

DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Who this might be right for
Renal Cell Carcinoma (RCC)Urothelial CarcinomaPrimary Peritoneal Cancer+3 more
Sumitomo Pharma America, Inc. 47
Testing effectiveness (Phase 2)Looking for participantsNCT05914116
What this trial is testing

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumors
DualityBio Inc. 862
Testing effectiveness (Phase 2)Looking for participantsNCT05081609
What this trial is testing

Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Who this might be right for
Advanced Solid TumorLocally Advanced Solid TumorMetastatic Solid Tumor+10 more
Ascendis Pharma Oncology Division A/S 345
Post-approval studies (Phase 4)Not Yet RecruitingNCT07075250
What this trial is testing

Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study

Who this might be right for
Platinum-resistant Ovarian Cancer (PROC)
Peking University People's Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT05824975
What this trial is testing

Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+6 more
GI Innovation, Inc. 358
Large-scale testing (Phase 3)Ended earlyNCT05092360
What this trial is testing

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

Who this might be right for
Platinum-resistant Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Mural Oncology, Inc 456
Testing effectiveness (Phase 2)Active Not RecruitingNCT05446298
What this trial is testing

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Who this might be right for
Ovarian CancerHigh Grade Serous Adenocarcinoma of OvaryPrimary Peritoneal Carcinoma+1 more
OncoC4, Inc. 58
Testing effectiveness (Phase 2)Looking for participantsNCT06303505
What this trial is testing

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Who this might be right for
Ovarian CancerNon-small Cell Lung Cancer
Tubulis GmbH 200
Testing effectiveness (Phase 2)Ended earlyNCT01991210
What this trial is testing

DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)

Who this might be right for
Ovarian Cancer
Genentech, Inc. 95
Testing effectiveness (Phase 2)Study completedNCT05044871
What this trial is testing

Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer

Who this might be right for
Ovarian Cancer
Tongji Hospital 108
Large-scale testing (Phase 3)Looking for participantsNCT06619236
What this trial is testing

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

Who this might be right for
Platinum-resistant Ovarian Cancer
Genmab 530
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07314619
What this trial is testing

Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer (PROC)
The First Affiliated Hospital of Zhengzhou University 30
Testing effectiveness (Phase 2)Ended earlyNCT05243524
What this trial is testing

Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

Who this might be right for
Platinum-resistant Epithelial Ovarian Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.) 16
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06600841
What this trial is testing

Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer

Who this might be right for
Platinum-resistant Ovarian Cancer (PROC)Immunotherapy
Fujian Cancer Hospital 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT06334432
What this trial is testing

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorHER2-negative Breast CancerMetastatic Castration-resistant Prostate Cancer (mCRPC)+2 more
Nuvation Bio Inc. 466
Testing effectiveness (Phase 2)Study completedNCT05613088
What this trial is testing

MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Neoplasms, Ovarian
Bristol-Myers Squibb 106
Testing effectiveness (Phase 2)Looking for participantsNCT06526819
What this trial is testing

SMP-3124LP in Adults With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Sumitomo Pharma America, Inc. 120
Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 764